Why Bank Stocks Can Fall When Interest Rates Rise: The Hidden Cost of Deposits

Higher interest rates should be good for banks.

Banks lend money at higher rates, earn more interest and make more profit.

Right?

Not always.

For bank stocks, the real question is not simply how much a bank earns on loans.

It is:

How much does the bank earn on its assets compared with what it must pay for its funding?

That difference can determine whether higher rates help—or hurt—profits.

How Banks Make Money

A simplified bank model looks like this:

Deposits → loans and investments → interest income

Suppose a bank:

  • pays depositors 1%
  • lends money at 5%

The gap is roughly:

4 percentage points

That spread helps generate the bank’s net interest income.

When rates rise, loan yields may increase.

But depositors eventually want higher rates too.

That is where the problem begins.

The Hidden Cost of Deposits

Imagine rates rise sharply.

The bank’s average loan yield increases from:

5% → 6%

Good news.

But customers can now earn attractive rates from money-market funds, Treasury bills and competing banks.

To keep deposits, the bank raises its deposit rate:

1% → 3.5%

The economics have changed.

Before:

5% − 1% = 4% spread

After:

6% − 3.5% = 2.5% spread

The bank is charging borrowers more—but its funding has become much more expensive.

Profitability can therefore fall even though interest rates increased.

Why Deposits Matter So Much

Deposits are generally one of a bank’s most important funding sources.

Stable, low-cost deposits are valuable because banks can use that money to make loans or purchase securities.

But customers have choices.

When market rates rise, they may move cash into:

  • high-yield savings accounts
  • money-market funds
  • Treasury bills
  • certificates of deposit

Banks may then need to increase deposit rates or replace lost deposits with more expensive funding.

Both can pressure profits.

What Is Net Interest Margin?

One of the most important metrics for bank stocks is net interest margin, or NIM.

In simple terms, it measures the difference between what a bank earns on interest-producing assets and what it pays to finance them.

Higher rates can improve NIM when asset yields rise faster than funding costs.

But if deposit costs catch up quickly:

higher rates → higher funding costs → lower margins

This is why investors closely watch deposit pricing during bank earnings.

Higher Rates Create Another Risk

Banks also own large portfolios of bonds.

When market interest rates rise:

bond prices fall

A bank may intend to hold those securities until maturity, but large unrealized losses can still create concerns about liquidity and balance-sheet strength.

So rapidly rising rates can hit banks from two directions:

more expensive deposits + falling bond values

That makes the relationship between rates and bank stocks far more complicated than it first appears.

Expected Return vs Risk

Higher rates can still be positive for banks.

The best environment is often one where:

loan yields rise faster than deposit costs

That can expand margins and earnings.

But investors should watch the trade-off.

Potential UpsidePotential Risk
Higher loan yieldsHigher deposit costs
Stronger net interest incomeDeposit outflows
Better lending marginsBond losses
Faster loan growthMore borrower defaults

A bank with cheap, loyal deposits may benefit significantly from higher rates.

A bank dependent on expensive funding may not.

What Investors Should Watch

When analysing bank stocks, focus on:

Net interest margin — Is the lending spread improving?

Deposit costs — How much is the bank paying customers?

Deposit growth — Is money staying at the bank?

Credit quality — Are borrowers still repaying loans?

Bond exposure — How sensitive is the balance sheet to rates?

These figures can explain much more than the headline interest-rate decision.

The Bottom Line

Higher interest rates do not automatically mean higher bank profits.

The real relationship is:

interest earned − funding cost = banking economics

If loan yields rise faster than deposit costs, bank profits can improve.

But if depositors demand much higher returns, margins can shrink.

That is why bank stocks can fall even while interest rates are rising.

For more macro analysis, risk research and model-driven market tools, sign up to TradingSimuLab and explore the Macro Model and Risk Simulation framework alongside the wider five-model research suite.

Continue exploring TradingSimuLab.

  • Software Stocks: Can AI Turn From a Threat Into a Revenue Opportunity?

    If artificial intelligence could build applications, automate workflows and let companies create their own tools, why keep paying large subscription fees to traditional software providers? That fear hit companies such as Salesforce and ServiceNow hard. Now the story may be changing. Salesforce recently reported its strongest growth in net new annual order value in four…

  • AI Training Data: Is Data Becoming More Valuable Than the Model?

    The AI race is no longer only about building bigger models. Increasingly, it is also about building better data. That shift is visible in the rise of Snorkel AI, which recently raised $350 million at a $3.5 billion valuation as demand grows for specialized datasets, reinforcement-learning environments and expert-generated training material. Its annualized revenue has…

  • Why Shipping Costs Can Move Oil Prices Even When Supply Is Available

    Oil prices can rise even when plenty of crude exists. One reason is often overlooked: shipping costs. Recent Venezuelan crude trades show the problem clearly. Reuters reported that tanker costs from Venezuela’s Jose port to the U.S. Gulf had risen to roughly $3.5 million per Aframax voyage, forcing traders to demand deeper discounts on the…

  • Currency Intervention Explained: Can Governments Stop a Falling Currency?

    A currency can keep falling even after interest rates rise. That is exactly why currency intervention periodically returns to the spotlight. The Japanese yen recently traded around 157.5 per U.S. dollar despite the Bank of Japan raising its policy rate to 1.25%. Markets remain alert to another possible intervention after reports of Japanese authorities checking…

  • India Stock Market: Why Global Banks Are Rushing Back In

    Global banks are paying closer attention to India’s capital markets. HSBC is preparing to re-enter India’s equity-broking business after more than a decade away, rebuilding its equities platform as IPO activity and demand from wealthy investors expand. Reuters reports that the bank is hiring for cash-equities and institutional-broking roles and may also relaunch retail broking…

  • Solar Stocks India: Can Domestic Panel Makers Compete With China?

    India is building a much larger domestic solar manufacturing industry. One of the clearest signs is Avaada Electro, which is preparing a major IPO as it expands solar-cell and module production. The company currently has about 8.5 GW of module capacity and is targeting 13.6 GW, alongside major expansion in solar-cell manufacturing. For investors watching…

  • Japan Bond Yields: Why Higher Rates Can Move Global Markets

    For decades, Japanese investors sent enormous amounts of money overseas in search of higher returns. That may be starting to change. Japan bond yields recently pushed above 3% on the 10-year government bond, the highest level since 1996. At the same time, Japanese investors have begun reducing some overseas bond exposure as domestic bonds become…

  • Corporate Governance Explained: Why Shareholder Rights Matter as Much as Earnings

    Investors spend enormous amounts of time studying revenue, margins and earnings. But sometimes the biggest risk sits somewhere else: Who actually controls the company? A recent dispute inside India’s Tata Group has brought corporate governance back into focus. Tata Sons and its controlling shareholder, Tata Trusts, have clashed over board authority, the reappointment of chairman…

  • Pharmaceutical Stocks: Why Europe Is Losing Ground in Drug Research

    Europe has some of the world’s largest pharmaceutical companies. But an increasing share of global drug research is happening elsewhere. European drugmakers say the region’s share of global pharmaceutical R&D has fallen from about 43% to 31%, while its share of commercial clinical trials has dropped to roughly 9% over the past decade. Industry leaders…